New knowledge about the gut microbiota and its interaction with the host’s metabolic regulation has emerged during the last few decades. Several factors may affect the composition of the gut microbiota, including dietary fiber. Dietary fiber is not hydrolyzed by human digestive enzymes, but it is acted upon by gut microbes, and metabolites like short-chain fatty acids are produced. The short-chain fatty acids may be absorbed into the circulation and affect metabolic regulation in the host or be a substrate for other microbes. Some studies have shown improved insulin sensitivity, weight regulation, and reduced inflammation with increases in gut-derived short-chain fatty acids, all of which may reduce the risk of developing metabolic diseases. To what extent a dietary intervention with fiber may affect the human gut microbiota and hence metabolic regulation, is however, currently not well described. The aim of the present review is to summarize recent research on human randomized, controlled intervention studies investigating the effect of dietary fiber on gut microbiota and metabolic regulation. Metabolic regulation is discussed with respect to markers relating to glycemic regulation and lipid metabolism. Taken together, the papers on which the current review is based, suggest that dietary fiber has the potential to change the gut microbiota and alter metabolic regulation. However, due to the heterogeneity of the studies, a firm conclusion describing the causal relationship between gut microbiota and metabolic regulation remains elusive.
there is a growing awareness of the importance of indoor microbiomes for human health. Given their complexity, these microbiomes can only be adequately surveyed using high throughput sequencing techniques. oxford nanopore's Minion is the newest third generation sequencing technology on the market. With its many advantages such as portability, user friendliness, simplicity, speed of sequencing and long read length, the technology is now an actual contender to established sequencing platforms. MinION's main disadvantage is a relatively low read accuracy compared to several other platforms, although this is constantly improving. The present study, which appears to be the first of its kind, provides the results of a preliminary analysis of the microbial communities in indoor environments based on 16S rRNA gene amplicon sequencing, using both the Oxford Nanopore Technologies (ONT) MinIOn and the Illumina MiSeq DNA sequencers. At the level of family and above, there was no significant difference between the microbial compositions as revealed by the two platforms. However, at the genus, and particularly at the species level, the ONT MinION reported greater taxonomic resolution than illumina MiSeq.
Escherichia albertii is an emerging human enteric pathogen (1). It belongs to the attaching and effacing group of bacteria, which also includes enteropathogenic and Shiga toxin-producing Escherichia coli (EPEC and STEC, respectively). Shiga toxin-producing E. albertii has been described, however, only in association with Shiga toxin (stx) subtype 2f (2). Sporadic infections as well as foodborne outbreaks caused by E. albertii have been reported, although rarely (3, 4). The prevalence, epidemiology, and clinical relevance of E. albertii are poorly understood, probably due to underestimation and misclassification of this pathogen (4). The phenotypic features distinguishing E. albertii from E. coli include a negative indole reaction and an inability to ferment lactose-, Dsorbitol, and D-xylose (1).In Norway, all presumptive enteropathogenic E. coli strains isolated from humans are submitted to the National Reference Laboratory for Enteropathogenic Bacteria for biochemical verification and for classification into well-known pathotypes according to virulence genes present (L. T. Brandal, A. L. Wester, H. Lange, I. Løbersli, B. A. Lindstedt, L. Vold, and G. Kapperud, submitted for publication). For outbreak detection purposes, all E. coli isolates are investigated with a generic multilocus variable-number tandem-repeat analysis (MLVA) (5).By these routine analyses, a nonmotile, -D-glucuronidase-, lactose-, and xylose-negative isolate with eae and stx 2 was identified. This isolate had an MLVA profile often seen in E. albertii (NA-NA-NA-NA-NA-NA-5-X-X-NA, where NA designates a locus not present and X indicates different repeat numbers). A PCR specific for E. albertii was conducted (6), and 16S rRNA sequencing was performed (MicroSEC 500 16S rRNA gene bacterial sequencing kit; Life Technologies), both of which confirmed the isolate as E. albertii. stx 2 was subtyped and sequenced (7), and the expression of the stx 2a gene was verified (ImmunoCard STAT!EHEC; Meridian Bioscience Europe). All E. albertii isolates identified from 2008 to 2014 (n ϭ 39) were examined for the presence of stx 2f (8) and the cytolethal distending toxin B gene (cdtB) (9).Interestingly, the E. albertii isolate identified in the present study carried stx 2a , hitherto never reported in E. albertii. Additionally, we showed that stx 2a was expressed. This indicates that E. albertii is able to transduce not only stx 2f -carrying bacteriophages but also stx 2a -carrying bacteriophages. STEC harboring eae and stx 2a are considered highly virulent and have the ability to induce life-threatening hemolytic uremic syndrome (HUS) in infected patients (10). In contrast, STEC harboring stx 2f are associated with milder symptoms (11) and have, to our knowledge, never previously been detected in HUS patients. The patient infected with stx 2a -positive E. albertii was 48 years old, had bloody diarrhea, and was infected in Norway (Table 1). Domestically acquired E. albertii infection was commonly seen in patients included in the present study; however, the majori...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.